Chardan lowered the firm’s price target on Century Therapeutics (IPSC) to $7 from $11 and keeps a Buy rating on the shares. The company reported Q4 results and announced a pipeline re-prioritization, including discontinuation of the Phase I ELiPSE-1 trial evaluating the company’s lead CD19 CAR-iNK candidate CNTY-01 in late-stage non-Hodgkin’s lymphoma, the analyst tells investors in a research note. The firm cut the price target to reflect the pipeline prioritization.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics price target lowered to $5 from $12 at Guggenheim
- Century Therapeutics Reports 2024 Financial Results and Strategic Updates
- Century Therapeutics price target lowered to $2 from $4 at Piper Sandler
- Century Therapeutics Re-prioritizes Pipeline for Key Programs
- Century Therapeutics trading resumes